Trump Revives ACA Debate, Faces Pushback Amid Biden’s Healthcare Emphasis
Donald Trump has recently reignited the debate over the Affordable Care Act (ACA), also known as [...]
Harvard Researchers Urge Removal of Single Orphan Drug Exemption in Inflation Reduction Act
Biopharma companies are protesting the Inflation Reduction Act's (IRA) pricing negotiations for drugs with multiple orphan [...]
Long-lasting Impact of Childhood Gun Injuries on Survivors and Families and the Importance of Gun Safety Promotion
Firearms have been the leading cause of death among children and teens in the U.S. since [...]
Updated ACS Lung Cancer Screening Guidelines: Redefining High-Risk Criteria, Expanding Age Range, and Easing Smoking History Requirements
The American Cancer Society (ACS) has updated its recommendations for lung cancer screening, dropping the criterion [...]
Biden Orders Healthcare Agencies to Develop Regulation Plan for AI Tools
President Biden has directed the Department of Health and Human Services and other leading health agencies [...]
Public Health Policies Aligned with Climate Change Mitigation: An Investment for Health and Economic Benefits
Investing in public health policies aligning with climate change mitigation measures is financially beneficial and crucial for human and planetary [...]
Federal Judge Upholds Medicare Drug Price Negotiation Provisions of Inflation Reduction Act
A federal judge has upheld the Medicare drug price negotiation provisions of the Inflation Reduction Act (IRA), opposing the Chamber [...]
Novo Nordisk Joins Biopharma Companies Challenging Drug Price Negotiations in Inflation Reduction Act
Novo Nordisk and numerous other biopharma companies are challenging drug price negotiation provisions in the Inflation Reduction Act. Novo has [...]
Class-Action Lawsuit Targets Johnson & Johnson and IBM after Data Breach
Johnson & Johnson and IBM face a proposed class-action lawsuit following a data breach at J&J’s [...]
Pharmaceutical Companies Sue Biden Administration Over Alleged APA Violations in Medicare Drug Pricing Program
Pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim, are suing the Biden Administration over its plan to [...]
Genentech to Pay $158,208 for Environmental Violations
Genentech has agreed to pay a $158,208 fine to the U.S. Environmental Protection Agency (EPA) over environmental violations at its [...]
Medicare Drug Price Negotiations Predicted to Yield $1.8 Billion Savings by 2026
A new report asserts that the Inflation Reduction Act will enforce a minimum discount that surpasses the 2020 rebates for [...]
Proposing a Revolution in American Healthcare: Universal Basic Health Coverage
MIT Professors Amy Finkelstein and Liran Einav have proposed a total overhaul of the U.S. health insurance system, advocating for [...]
FTC Sues to Block IQVIA’s Acquisition of Propel Media
The Federal Trade Commission (FTC) is attempting to block IQVIA Holdings from acquiring Propel Media, Inc., arguing that it would [...]
Unmasking Healthcare Costs: Beyond Transparency
What You Need to Know: Policymakers have shifted focus towards price transparency in healthcare to combat escalating costs; however, merely [...]
Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster
What You Need to Know: Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira [...]
Will the Medicare Price Negotiation Revamp Sufficiently Appease Pharma Companies?
The Centers for Medicare & Medicaid Services (CMS) amendments to its drug pricing negotiation program will unlikely deter past, current, [...]
Podcast Q&A: Medicare Data for RWD Analysis
Experts answer questions on the how and why use of Medicare data for conducting various types of RWD analysis is important.
Endpoints at #DIA23
The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who will provide a practical overview of how and why to use data from Medicare for real world studies.
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval
As we adjust to the post-COVID environment, hear from industry leaders about the biotech global investment and drug pipeline environment. In addition, we'll look at why biotech companies are increasingly exploring clinical opportunities in APAC, to achieve FDA accepted data and what actionable strategies can be implemented to leverage APAC's streamlined regulatory processes and accelerated clinical development. Our Regulatory affairs leaders from North America and Australia will share insight into processes supporting a robust clinical program, and how Phase 1 FDA accepted data from Australia, specifically, can launch global drug development programs.
Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with [...]
Podcast Q&A: Embracing FDA Guidance on Real World Data
Experts answer questions on embracing FDA’s guidance on the use of real world data (RWD) to understand how your organization can navigate data quality, curation, and management challenges for better research.
